Vertex Pharmaceuticals Soars 3.36% on Strong Revenue Growth

Vertex Pharmaceuticals Inc. rose 3.36% in pre-market trading on April 2, 2025, reflecting a positive sentiment among investors.

Vertex Pharmaceuticals Inc. has been the subject of recent analyst updates. RBC Capital maintained its rating for the company as "sector perform," with a target price of $420.00. This comes after the company released its 2024 annual report, which showed a year-over-year increase in revenue of 11.66% to $110.20 billion, but a net loss of $5.36 billion, resulting in a basic earnings per share of -$2.08.

Vertex Pharmaceuticals Inc. is a global biotechnology company focused on developing and commercializing small molecule drugs for serious diseases. The company's portfolio includes treatments for cystic fibrosis, infectious diseases, autoimmune diseases, cancer, inflammatory bowel disease, and neurological disorders. Vertex Pharmaceuticals has collaborations with leading pharmaceutical companies, non-profit disease research organizations, and academic institutions worldwide.